Barry J. Simon, M.D., is a healthcare executive with more than 30 years of experience spanning the public and private sectors. He previously served on Viracta’s board from July 2017 to November 2020 and has been serving as Director and CCAO of Immunity Bio, Inc. since March 2021. Prior to this, he served as President and Chief Administrative Officer of Nantkwest, Inc. since 2015 and as its President and CEO since 2007. Dr. Simon also serves on the boards of Cue BioPharma and Brink Biologics Inc. Previously, he held Vice President, senior level and advisory positions at F. Hoffmann-La Roche, Roche Labs, Connetics Corporation, Immunomedics, Immusol, HealthPro BioVentures, LLC, and NorthSound Capital, LLC. He received his M.D. from the SUNY Downstate Health Sciences Center in New York and trained clinically in infectious diseases, anesthesiology, and internal medicine at Albert Einstein College of Medicine, The Mount Sinai Medical Center and New York University, respectively.